STAAR Surgical Company Logo

STAAR Surgical Company

STAA

(2.2)
Stock Price

24,82 USD

3.25% ROA

5.39% ROE

93.03x PER

Market Cap.

1.547.460.772,00 USD

8.87% DER

0% Yield

6.38% NPM

STAAR Surgical Company Stock Analysis

STAAR Surgical Company Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

STAAR Surgical Company Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (9%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 ROE

The stock's ROE falls within an average range (5.61%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (4.19%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (886), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 PBV

The stock's elevated P/BV ratio (4.47x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

STAAR Surgical Company Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

STAAR Surgical Company Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

STAAR Surgical Company Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

STAAR Surgical Company Revenue
Year Revenue Growth
1988 6.800.000
1989 4.500.000 -51.11%
1990 4.500.000 0%
1991 4.300.000 -4.65%
1992 10.200.000 57.84%
1993 20.100.000 49.25%
1994 27.400.000 26.64%
1995 34.700.000 21.04%
1996 42.200.000 17.77%
1997 42.500.000 0.71%
1998 54.200.000 21.59%
1999 59.000.000 8.14%
2000 53.985.872 -9.29%
2001 50.237.000 -7.46%
2002 48.248.000 -4.12%
2003 50.458.000 4.38%
2004 51.685.000 2.37%
2005 51.303.000 -0.74%
2006 56.282.000 8.85%
2007 59.363.000 5.19%
2008 74.894.000 20.74%
2009 75.345.000 0.6%
2010 54.958.000 -37.1%
2011 62.765.000 12.44%
2012 63.783.000 1.6%
2013 72.215.000 11.68%
2014 74.987.000 3.7%
2015 77.123.000 2.77%
2016 82.432.000 6.44%
2017 90.611.000 9.03%
2018 123.954.000 26.9%
2019 150.185.000 17.47%
2020 163.460.000 8.12%
2021 230.472.000 29.08%
2022 284.391.000 18.96%
2023 321.232.000 11.47%
2023 322.415.000 0.37%
2024 396.020.000 18.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

STAAR Surgical Company Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 2.700.000 100%
1995 3.300.000 18.18%
1996 4.100.000 19.51%
1997 3.900.000 -5.13%
1998 3.600.000 -8.33%
1999 4.300.000 16.28%
2000 4.215.106 -2.01%
2001 3.800.000 -10.92%
2002 4.016.000 5.38%
2003 5.120.000 21.56%
2004 6.246.000 18.03%
2005 5.573.000 -12.08%
2006 7.080.000 21.29%
2007 6.711.000 -5.5%
2008 7.938.000 15.46%
2009 5.893.000 -34.7%
2010 5.724.000 -2.95%
2011 5.868.000 2.45%
2012 6.444.000 8.94%
2013 6.708.000 3.94%
2014 12.363.000 45.74%
2015 14.761.000 16.25%
2016 20.294.000 27.26%
2017 19.116.000 -6.16%
2018 22.028.000 13.22%
2019 25.298.000 12.93%
2020 31.918.000 20.74%
2021 33.862.000 5.74%
2022 35.983.000 5.89%
2023 45.880.000 21.57%
2023 44.401.000 -3.33%
2024 56.216.000 21.02%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

STAAR Surgical Company General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 8.593.000 100%
2001 8.746.000 1.75%
2002 0 0%
2003 9.343.000 100%
2004 9.343.000 0%
2005 9.343.000 0%
2006 9.343.000 0%
2007 12.951.000 27.86%
2008 15.730.000 17.67%
2009 15.710.000 -0.13%
2010 14.078.000 -11.59%
2011 15.992.000 11.97%
2012 17.786.000 10.09%
2013 18.810.000 5.44%
2014 18.481.000 -1.78%
2015 19.604.000 5.73%
2016 22.252.000 11.9%
2017 20.665.000 -7.68%
2018 24.287.000 14.91%
2019 29.313.000 17.15%
2020 33.911.000 13.56%
2021 44.142.000 23.18%
2022 54.742.000 19.36%
2023 77.064.000 28.97%
2023 72.319.000 -6.56%
2024 94.564.000 23.52%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

STAAR Surgical Company EBITDA
Year EBITDA Growth
1988 -1.300.000
1989 -2.700.000 51.85%
1990 -14.100.000 80.85%
1991 -10.500.000 -34.29%
1992 -6.500.000 -61.54%
1993 2.100.000 409.52%
1994 6.000.000 65%
1995 8.000.000 25%
1996 11.800.000 32.2%
1997 9.800.000 -20.41%
1998 10.300.000 4.85%
1999 7.900.000 -30.38%
2000 -11.440.821 169.05%
2001 773.000 1580.05%
2002 -2.320.000 133.32%
2003 -3.090.000 24.92%
2004 -7.564.000 59.15%
2005 -8.753.000 13.58%
2006 -11.510.000 23.95%
2007 -11.004.000 -4.6%
2008 -16.587.000 33.66%
2009 74.000 22514.86%
2010 -153.000 148.37%
2011 5.081.000 103.01%
2012 1.622.000 -213.26%
2013 3.396.000 52.24%
2014 -5.135.000 166.13%
2015 -2.127.000 -141.42%
2016 -9.290.000 77.1%
2017 -1.096.000 -747.63%
2018 9.895.000 111.08%
2019 16.068.000 38.42%
2020 9.000.000 -78.53%
2021 39.945.000 77.47%
2022 50.018.000 20.14%
2023 36.088.000 -38.6%
2023 33.220.999 -8.63%
2024 53.680.000 38.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

STAAR Surgical Company Gross Profit
Year Gross Profit Growth
1988 -1.200.000
1989 -2.700.000 55.56%
1990 2.500.000 208%
1991 2.300.000 -8.7%
1992 7.800.000 70.51%
1993 17.000.000 54.12%
1994 22.600.000 24.78%
1995 27.800.000 18.71%
1996 34.300.000 18.95%
1997 35.700.000 3.92%
1998 40.100.000 10.97%
1999 40.300.000 0.5%
2000 31.386.989 -28.4%
2001 22.034.000 -42.45%
2002 24.149.000 8.76%
2003 27.837.000 13.25%
2004 26.143.000 -6.48%
2005 23.786.000 -9.91%
2006 26.433.000 10.01%
2007 29.266.000 9.68%
2008 40.107.000 27.03%
2009 41.893.000 4.26%
2010 35.076.000 -19.43%
2011 42.369.000 17.21%
2012 44.291.000 4.34%
2013 50.309.000 11.96%
2014 48.823.000 -3.04%
2015 52.723.000 7.4%
2016 58.369.000 9.67%
2017 64.280.000 9.2%
2018 91.510.000 29.76%
2019 111.954.000 18.26%
2020 118.362.000 5.41%
2021 178.637.000 33.74%
2022 223.383.000 20.03%
2023 254.552.000 12.24%
2023 252.651.000 -0.75%
2024 313.648.000 19.45%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

STAAR Surgical Company Net Profit
Year Net Profit Growth
1988 -3.800.000
1989 -4.400.000 13.64%
1990 3.500.000 225.71%
1991 -11.300.000 130.97%
1992 -5.100.000 -121.57%
1993 2.500.000 304%
1994 8.300.000 69.88%
1995 7.500.000 -10.67%
1996 6.900.000 -8.7%
1997 7.400.000 6.76%
1998 2.400.000 -208.33%
1999 2.200.000 -9.09%
2000 -18.901.599 111.64%
2001 -14.833.000 -27.43%
2002 -17.158.000 13.55%
2003 -8.357.000 -105.31%
2004 -11.332.000 26.25%
2005 -11.175.000 -1.4%
2006 -15.044.000 25.72%
2007 -15.999.000 5.97%
2008 -23.195.000 31.02%
2009 -6.200.000 -274.11%
2010 53.000 11798.11%
2011 1.348.000 96.07%
2012 -1.763.000 176.46%
2013 398.000 542.96%
2014 -8.392.000 104.74%
2015 -6.533.000 -28.46%
2016 -12.129.000 46.14%
2017 -2.139.000 -467.04%
2018 4.968.000 143.06%
2019 14.048.000 64.64%
2020 5.913.000 -137.58%
2021 27.511.000 78.51%
2022 39.665.000 30.64%
2023 19.268.000 -105.86%
2023 21.347.000 9.74%
2024 29.516.000 27.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

STAAR Surgical Company Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 -2
1989 -2 0%
1990 1 200%
1991 -1 200%
1992 -1 0%
1993 0 0%
1994 1 0%
1995 1 0%
1996 1 0%
1997 1 0%
1998 0 0%
1999 0 0%
2000 -1 100%
2001 -1 0%
2002 -1 100%
2003 0 0%
2004 -1 0%
2005 0 0%
2006 -1 0%
2007 -1 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 1 0%
2023 0 0%
2023 0 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

STAAR Surgical Company Free Cashflow
Year Free Cashflow Growth
1990 -600.000
1991 -5.400.000 88.89%
1992 -5.000.000 -8%
1993 -2.100.000 -138.1%
1994 1.800.000 216.67%
1995 1.500.000 -20%
1996 4.200.000 64.29%
1997 4.800.000 12.5%
1998 2.300.000 -108.7%
1999 -100.000 2400%
2000 -8.711.683 98.85%
2001 -3.738.000 -133.06%
2002 -305.000 -1125.57%
2003 -5.455.000 94.41%
2004 -10.509.000 48.09%
2005 -8.170.000 -28.63%
2006 -9.426.000 13.32%
2007 -11.875.000 20.62%
2008 -9.320.000 -27.41%
2009 841.000 1208.2%
2010 -4.737.000 117.75%
2011 4.384.000 208.05%
2012 906.000 -383.89%
2013 -96.000 1043.75%
2014 -12.005.000 99.2%
2015 -4.205.000 -185.49%
2016 -2.156.000 -95.04%
2017 1.807.000 219.31%
2018 10.522.000 82.83%
2019 15.617.000 32.62%
2020 12.547.000 -24.47%
2021 30.317.000 58.61%
2022 17.607.000 -72.19%
2023 -15.160.000 216.14%
2023 -3.594.000 -321.81%
2024 -16.649.000 78.41%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

STAAR Surgical Company Operating Cashflow
Year Operating Cashflow Growth
1990 -100.000
1991 -4.900.000 97.96%
1992 -3.100.000 -58.06%
1993 -1.000.000 -210%
1994 4.000.000 125%
1995 5.000.000 20%
1996 8.500.000 41.18%
1997 7.600.000 -11.84%
1998 4.300.000 -76.74%
1999 4.900.000 12.24%
2000 -5.372.576 191.2%
2001 -2.558.000 -110.03%
2002 569.000 549.56%
2003 -4.146.000 113.72%
2004 -8.804.000 52.91%
2005 -6.976.000 -26.2%
2006 -8.647.000 19.32%
2007 -11.184.000 22.68%
2008 -8.228.000 -35.93%
2009 1.427.000 676.59%
2010 -4.417.000 132.31%
2011 5.346.000 182.62%
2012 3.217.000 -66.18%
2013 3.352.000 4.03%
2014 -7.951.000 142.16%
2015 -2.162.000 -267.76%
2016 1.049.000 306.1%
2017 2.853.000 63.23%
2018 12.767.000 77.65%
2019 25.795.000 50.51%
2020 20.951.000 -23.12%
2021 43.962.000 52.34%
2022 35.715.000 -23.09%
2023 -5.975.000 697.74%
2023 14.594.000 140.94%
2024 -10.413.000 240.15%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

STAAR Surgical Company Capital Expenditure
Year Capital Expenditure Growth
1990 500.000
1991 500.000 0%
1992 1.900.000 73.68%
1993 1.100.000 -72.73%
1994 2.200.000 50%
1995 3.500.000 37.14%
1996 4.300.000 18.6%
1997 2.800.000 -53.57%
1998 2.000.000 -40%
1999 5.000.000 60%
2000 3.339.107 -49.74%
2001 1.180.000 -182.98%
2002 874.000 -35.01%
2003 1.309.000 33.23%
2004 1.705.000 23.23%
2005 1.194.000 -42.8%
2006 779.000 -53.27%
2007 691.000 -12.74%
2008 1.092.000 36.72%
2009 586.000 -86.35%
2010 320.000 -83.13%
2011 962.000 66.74%
2012 2.311.000 58.37%
2013 3.448.000 32.98%
2014 4.054.000 14.95%
2015 2.043.000 -98.43%
2016 3.205.000 36.26%
2017 1.046.000 -206.41%
2018 2.245.000 53.41%
2019 10.178.000 77.94%
2020 8.404.000 -21.11%
2021 13.645.000 38.41%
2022 18.108.000 24.65%
2023 9.185.000 -97.15%
2023 18.188.000 49.5%
2024 6.236.000 -191.66%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

STAAR Surgical Company Equity
Year Equity Growth
1988 -4.000.000
1989 -8.000.000 50%
1990 100.000 8100%
1991 4.300.000 97.67%
1992 7.300.000 41.1%
1993 12.000.000 39.17%
1994 22.000.000 45.45%
1995 28.700.000 23.34%
1996 36.600.000 21.58%
1997 44.800.000 18.3%
1998 48.600.000 7.82%
1999 53.200.000 8.65%
2000 58.668.801 9.32%
2001 46.828.000 -25.29%
2002 30.651.000 -52.78%
2003 35.423.000 13.47%
2004 37.862.000 6.44%
2005 40.366.000 6.2%
2006 31.760.000 -27.1%
2007 36.225.000 12.33%
2008 16.027.000 -126.02%
2009 21.070.000 23.93%
2010 22.427.000 6.05%
2011 29.458.000 23.87%
2012 31.742.000 7.2%
2013 38.852.000 18.3%
2014 37.099.000 -4.73%
2015 38.846.000 4.5%
2016 37.905.000 -2.48%
2017 42.936.000 11.72%
2018 132.426.000 67.58%
2019 159.884.000 17.17%
2020 197.222.000 18.93%
2021 258.558.000 23.72%
2022 332.442.000 22.22%
2023 385.954.000 13.86%
2023 378.595.000 -1.94%
2024 409.103.000 7.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

STAAR Surgical Company Assets
Year Assets Growth
1988 16.100.000
1989 13.300.000 -21.05%
1990 10.600.000 -25.47%
1991 9.400.000 -12.77%
1992 12.800.000 26.56%
1993 18.800.000 31.91%
1994 28.900.000 34.95%
1995 38.800.000 25.52%
1996 51.100.000 24.07%
1997 62.400.000 18.11%
1998 73.300.000 14.87%
1999 85.300.000 14.07%
2000 80.152.193 -6.42%
2001 65.805.000 -21.8%
2002 45.220.000 -45.52%
2003 47.219.000 4.23%
2004 51.973.000 9.15%
2005 52.755.000 1.48%
2006 47.770.000 -10.44%
2007 54.179.000 11.83%
2008 52.582.000 -3.04%
2009 58.681.000 10.39%
2010 40.585.000 -44.59%
2011 49.006.000 17.18%
2012 54.759.000 10.51%
2013 61.931.000 11.58%
2014 58.911.000 -5.13%
2015 62.954.000 6.42%
2016 65.443.000 3.8%
2017 67.932.000 3.66%
2018 167.339.000 59.4%
2019 206.865.000 19.11%
2020 257.416.000 19.64%
2021 345.778.000 25.55%
2022 415.148.000 16.71%
2023 488.692.000 15.05%
2023 471.521.000 -3.64%
2024 512.745.000 8.04%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

STAAR Surgical Company Liabilities
Year Liabilities Growth
1988 20.100.000
1989 21.300.000 5.63%
1990 10.500.000 -102.86%
1991 5.100.000 -105.88%
1992 5.500.000 7.27%
1993 6.800.000 19.12%
1994 6.900.000 1.45%
1995 10.100.000 31.68%
1996 14.500.000 30.34%
1997 17.600.000 17.61%
1998 24.700.000 28.74%
1999 32.100.000 23.05%
2000 21.483.392 -49.42%
2001 18.977.000 -13.21%
2002 14.569.000 -30.26%
2003 11.796.000 -23.51%
2004 14.111.000 16.41%
2005 12.389.000 -13.9%
2006 16.010.000 22.62%
2007 17.954.000 10.83%
2008 36.555.000 50.88%
2009 37.611.000 2.81%
2010 18.158.000 -107.13%
2011 19.548.000 7.11%
2012 23.017.000 15.07%
2013 23.079.000 0.27%
2014 21.812.000 -5.81%
2015 24.108.000 9.52%
2016 27.538.000 12.46%
2017 24.996.000 -10.17%
2018 34.913.000 28.4%
2019 46.981.000 25.69%
2020 60.194.000 21.95%
2021 87.220.000 30.99%
2022 82.706.000 -5.46%
2023 102.738.000 19.5%
2023 92.926.000 -10.56%
2024 103.642.000 10.34%

STAAR Surgical Company Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.78
Net Income per Share
0.34
Price to Earning Ratio
93.03x
Price To Sales Ratio
4.65x
POCF Ratio
41.48
PFCF Ratio
114.2
Price to Book Ratio
3.78
EV to Sales
4.18
EV Over EBITDA
41.94
EV to Operating CashFlow
37.33
EV to FreeCashFlow
102.65
Earnings Yield
0.01
FreeCashFlow Yield
0.01
Market Cap
1,55 Bil.
Enterprise Value
1,39 Bil.
Graham Number
7.96
Graham NetNet
4.54

Income Statement Metrics

Net Income per Share
0.34
Income Quality
2.24
ROE
0.04
Return On Assets
0.04
Return On Capital Employed
0.05
Net Income per EBT
0.62
EBT Per Ebit
1.36
Ebit per Revenue
0.08
Effective Tax Rate
0.38

Margins

Sales, General, & Administrative to Revenue
0.25
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.79
Operating Profit Margin
0.08
Pretax Profit Margin
0.1
Net Profit Margin
0.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.53
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.76
Free CashFlow per Share
0.28
Capex to Operating CashFlow
0.64
Capex to Revenue
0.07
Capex to Depreciation
4.34
Return on Invested Capital
0.03
Return on Tangible Assets
0.03
Days Sales Outstanding
104.92
Days Payables Outstanding
100.63
Days of Inventory on Hand
207.4
Receivables Turnover
3.48
Payables Turnover
3.63
Inventory Turnover
1.76
Capex per Share
0.48

Balance Sheet

Cash per Share
4,79
Book Value per Share
8,33
Tangible Book Value per Share
8.29
Shareholders Equity per Share
8.33
Interest Debt per Share
0.7
Debt to Equity
0.09
Debt to Assets
0.07
Net Debt to EBITDA
-4.72
Current Ratio
5.8
Tangible Asset Value
0,41 Bil.
Net Current Asset Value
0,28 Bil.
Invested Capital
432013000
Working Capital
0,32 Bil.
Intangibles to Total Assets
0
Average Receivables
0,08 Bil.
Average Payables
0,02 Bil.
Average Inventory
38931500
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

STAAR Surgical Company Dividends
Year Dividends Growth

STAAR Surgical Company Profile

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

CEO
Mr. Thomas G. Frinzi
Employee
1.056
Address
25651 Atlantic Ocean Drive
Lake Forest, 92630

STAAR Surgical Company Executives & BODs

STAAR Surgical Company Executives & BODs
# Name Age
1 Mr. Thomas G. Frinzi
President, Chief Executive Officer & Chairman
70
2 Dr. Keith Holliday Ph.D.
Chief Technology Officer
70
3 Mr. Brian Moore
Vice President of Investor Relations & Corporate Development
70
4 Ms. Nancy Sabin
Chief Marketing Officer
70
5 Dr. Magda Michna Ph.D.
Chief Clinical, Regulatory & Medical Affairs Officer
70
6 Mr. Warren Foust
Chief Operating Officer
70
7 Mr. James Francese
Senior Vice President of Commercial Operations - North America & APAC
70
8 Mr. Patrick F. Williams
Chief Financial Officer
70
9 Dr. Scott D. Barnes M.D.
Chief Medical Officer
70
10 Mr. Nathaniel B. Sisitsky Esq.
General Counsel & Corporate Secretary
70

STAAR Surgical Company Competitors